Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

American Beacon ARK Transformational Innovation Fund Institutional Class (ADNIX)

Net Asset Value
1 Day
Overall Morningstar Rating
Style or Category
No Load
Sales Expenses
Expense Ratio
Morningstar Risk Rating™
Investment Objective The investment seeks long-term growth of capital. Under normal circumstances- substantially all of the fund's assets are invested in a portfolio of equity securities including common stocks and other equity investments or ownership interests in business enterprises that are relevant to the fund's investment theme of transformational innovation. The fund's investments in foreign equity securities are in both developed and emerging markets. It invests in American Depositary Receipts (''ADRs'') and securities sold on foreign exchanges and securities denominated in foreign currencies when purchasing foreign equities. The fund is non-diversified.


1 month-2.01% 3 years--
3 months+18.17% 5 years--
1 year-- Since inception+68.28%
Data through --

Peer Comparisonvs. Technology

Performance 5-yr return--+19.49%
Expense ratio3.25%1.40%
Risk 5 year sharpe ratio--1.35
Net assets$11.0M$1.2B
Average market cap$9.6B$41.4B
Average P/E--26.2
Portfolio turnover----

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyAmerican Beacon
Fund manager & tenureCatherine Wood / 0 Years
Minimal initial investment$250,000.00
Minimum IRA investment--


U.S. stock79.91%
International stock13.36%
Fixed income0.00%
Top 5 Sectors
Portfolio weighting
Business service --
Consumer goods --
Consumer service --
Energy --
Financial service --
Top 10 Holdings
Portfolio weighting
GBTC Bitcoin Investment Trust9.05%
TSLA Tesla5.56%
SSYS Stratasys Ltd4.17%
AMZN Amazon3.89%
TWTR Twitter3.77%
ATHN athenahealth Inc3.52%
NTLA Intellia Therapeutics Inc3.22%
ILMN Illumina Inc3.12%
JUNO Juno Therapeutics Inc2.78%
EDIT Editas Medicine Inc2.69%